{"id":"W3012129470","doi":"10.1158/1538-7445.sabcs19-ot1-07-01","title":"Abstract OT1-07-01: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Lapatinib; Antibody-drug conjugate; Phases of clinical research; Cancer; Breast cancer; Antibody; Clinical trial; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001028709,0.001326277,0.001638748,0.0003301886,0.0002829687,0.0009140644,0.0006103936,0.001383191,0.01002876],"category_scores_gemma":[0.0007788297,0.0004853142,0.001295605,0.0003275278,0.000840899,0.0007553034,0.0002408506,0.003017937,0.001307155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009312028,"about_ca_system_score_gemma":0.00116358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001217887,"about_ca_topic_score_gemma":0.00299663,"domain_scores_codex":[0.9996535,0.0001579309,0.00002049729,0.00006626014,0.00002489768,0.0000769633],"domain_scores_gemma":[0.9994254,0.0001479941,0.0001074869,0.00003235398,0.00002582608,0.0002610078],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9677809,0.007537182,0.0004968356,0.0002361102,0.0004333788,0.00003320268,0.00002895321,0.0002949504,0.005299877,0.0001391917,0.001550196,0.01616922],"study_design_scores_gemma":[0.8639338,0.1304816,0.002192701,0.00002951876,0.000476181,0.00005171679,0.00002020727,0.0006332532,0.001052809,0.000153715,0.0009607107,0.00001367799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988843,0.002257088,0.000342236,0.0009534776,0.0005385695,0.00163073,0.001970926,0.0001362951,0.003327753],"genre_scores_gemma":[0.9873751,0.001602829,0.0008261944,0.001165406,0.0003822839,0.001382923,0.001955445,0.00002942307,0.005280377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01002876,"threshold_uncertainty_score":0.03354949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08177458749404355,"score_gpt":0.4152758576420249,"score_spread":0.3335012701479814,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}